New chemo cocktail targets liver tumors in pancreatic cancer

NCT ID NCT06538623

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a combination of chemotherapy drugs given directly into the liver artery for people with pancreatic cancer that had spread only to the liver and stopped responding to standard treatment. The 40 participants received a mix of oxaliplatin, irinotecan liposomes, fluorouracil, and leucovorin via hepatic artery infusion, followed by either more infusion or an oral chemo pill. The goal was to see if this approach could improve survival and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Liposomal irinotecan, oxaliplatin, fluorouracil, leucovorin, and tegafur/gimeracil/oteracil (S-1)
What this could lead to
If it works, this could offer a new second-line treatment option for people with pancreatic cancer that has spread only to the liver.
What could go wrong
This is a small, early-phase trial with only 40 people and no comparison group, so results may not be definitive. The chemotherapy combination also carries typical chemo side effects like nausea, fatigue, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC METASTASIS OF PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 2000010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.